Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy.

Autor: Jain R; University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Raksha.Jain@utsouthwestern.edu., Peng G; University of Texas Southwestern Medical Center, Dallas, TX., Lee M; University of Texas Southwestern Medical Center, Dallas, TX., Keller A; University of Texas Southwestern Medical Center, Dallas, TX., Cosmich S; University of Texas Southwestern Medical Center, Dallas, TX., Reddy S; University of Texas, Austin, TX., West NE; John Hopkins University, Baltimore, MD., Kazmerski TM; University of Pittsburgh, Pittsburgh, PA., Goralski JL; University of North Carolina, Chapel Hill, NC., Flume PA; Medical University of South Carolina, Charleston, SC., Roe AH; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA., Hadjiliadis D; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA., Uluer A; Harvard/Boston Children's Hospital and Brigham & Women's Hospital, Boston, MA., Mody S; University of California San Diego, San Diego, CA., Ladores S; University of Alabama at Birmingham, Birmingham, AL., Taylor-Cousar JL; National Jewish Health, Denver, CO; University of Colorado Anschutz Medical Campus, Aurora, CO.
Jazyk: angličtina
Zdroj: Chest [Chest] 2024 Sep 27. Date of Electronic Publication: 2024 Sep 27.
DOI: 10.1016/j.chest.2024.09.019
Abstrakt: Background: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are available to the majority of people with CF in the United States; little is known about pregnancy outcomes with modulator use. The aim of this retrospective study was to determine the impact of CFTR modulators on maternal outcomes.
Research Question: Does pregnancy differentially affect outcomes in female subjects with CF with and without CFTR modulator exposure?
Study Design and Methods: Data on pregnancies from 2010 to 2021 were collected from 11 US adult CF centers. Multivariable longitudinal regression analysis was performed to assess whether changes in percent predicted FEV 1 (ppFEV 1 ), BMI, pulmonary exacerbations (PEx), and Pseudomonas aeruginosa prevalence differed from prior to, during, and following pregnancy according to CFTR modulator use while adjusting for confounders. Infant outcomes are also described based on maternal modulator use.
Results: Among 307 pregnancies, mean age at conception was 28.5 years (range, 17-42 years), prepregnancy ppFEV 1 was 74.2, and BMI was 22.3 kg/m 2 . A total of 114 pregnancies (37.1%) had CFTR modulator exposure during pregnancy (77 with highly effective modulator therapy [HEMT] and 37 with other modulators). The adjusted mean change in ppFEV 1 from prepregnancy to during pregnancy was -2.36 (95% CI, -3.56 to -1.16) in the unexposed group and 2.60 (95% CI, 0.23 to 4.97) in the HEMT group, with no significant change from during pregnancy to 1 year postpregnancy. There was an overall decline in ppFEV 1 from prepregnancy to postpregnancy in the no modulator group (-2.56; 95% CI, -3.62 to -1.49) that was not observed in the HEMT group (1.10; 95% CI, -1.13 to 3.34). PEx decreased from prepregnancy to postpregnancy in the HEMT group, and BMI increased from prepregnancy to during pregnancy in all groups but with no significant change postpregnancy. Missing infant outcomes data precluded firm conclusions.
Interpretation: We observed superior pregnancy and postpregnancy pulmonary outcomes in individuals who used HEMT, including a preservation of ppFEV 1 , compared with those unexposed to HEMT.
Competing Interests: Financial/Nonfinancial Disclosures The authors declare that the research was conducted in the absence of any commercial or financial relationships that would cause bias to the content of this manuscript. J. L. T.-C,. M. L., A. W., N. E. W., T. M. K., A.U., A.H.R., S.L., J. L. G., D.H., S.M., P. A. F., and R. J. report Cystic Fibrosis Foundation institutional research funding for work related to the manuscript. Additional conflicts of interest unrelated to the content of the manuscript are included in the attached ICMJE disclosures. None declared: (G. P., S. C., S. R.).
(Copyright © 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: